摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-((4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan-4-yl)acetate methyl ester

中文名称
——
中文别名
——
英文名称
2-((4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan-4-yl)acetate methyl ester
英文别名
2-((4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate methyl ester;methyl 2-((4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate;pitavastatin acetonide methyl ester;methyl 2-[(4R,6S)-6-[(E)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate
2-((4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan-4-yl)acetate methyl ester化学式
CAS
——
化学式
C29H30FNO4
mdl
——
分子量
475.56
InChiKey
ZTRBPYDDCZGHQH-UQECUQMJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.4
  • 重原子数:
    35
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    57.6
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of Artificial HMG-CoA Reductase Inhibitors Based on the Olefination Strategy
    作者:Tamejiro Hiyama、Tatsuya Minami、Kyoko Takahashi
    DOI:10.1246/bcsj.68.364
    日期:1995.1
    Synthetic methods were studied for optically active 6-oxo-3,5-isopropylidenedioxyhexanoate esters (4), which could be used as a key precursor of various kinds of artificial analogs of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. An enantiomer (+)-4 was prepared by asymmetric reduction of β,δ-diketo esters derived from the Taber’s alcohol or l-tartrate followed by a series of chemical transformations, and the desired enantiomer (−)-4 was prepared by the same asymmetric reduction starting from d-tartrate. The key intermediate (−)-4 was finally converted into a highly potent HMG-CoA reductase inhibitor, NK-104.
    研究了合成光学活性6-氧代-3,5-异丙基二氧六酸酯(4)的方法,这些化合物可作为各种人工类3-羟基-3-甲基戊二酸辅酶AHMG-CoA)还原酶抑制剂的关键前体。通过对来自塔贝酒精或l-酒石酸盐的β,δ-二酮酯进行不对称还原,制备了对映异构体(+)-4,随后经过一系列化学转化,最终得到所需的对映异构体(−)-4,并通过相同的不对称还原方法从d-酒石酸盐出发制得。关键中间体(−)-4最终转化为一种高效的HMG-CoA还原酶抑制剂NK-104。
  • [EN] AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN<br/>[FR] SELS D'AMINE DE PITAVASTATINE ET DE ROSUVASTATINE
    申请人:DSM SINOCHEM PHARM NL BV
    公开号:WO2014154857A1
    公开(公告)日:2014-10-02
    The present invention relates to oxygen-comprising amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.
    本发明涉及含氧胺盐的HMG-CoA还原酶抑制剂,涉及生产该胺盐的方法,以及在生产HMG-CoA还原酶抑制剂的药用可接受盐中使用该胺盐的用途。
  • PHARMACEUTICALLY ACCEPTABLE AMINE SALTS OF PITAVASTATIN
    申请人:DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.
    公开号:US20160052887A1
    公开(公告)日:2016-02-25
    The present invention relates to pharmaceutically acceptable amine salts of pitavastatin and a method for producing pharmaceutically acceptable amine salts of pitavastatin. Also provided are pharmaceutical compositions of these amine salts or solvates thereof, and methods of their use as HMG-CoA reductase inhibitors.
    本发明涉及医药上可接受的匹伐他汀胺盐及其制备方法。还提供了这些胺盐或其溶剂的制药组合物,以及它们作为HMG-CoA还原酶抑制剂的使用方法。
  • AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN
    申请人:DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.
    公开号:US20160075664A1
    公开(公告)日:2016-03-17
    The present invention relates to oxygen-comprising amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.
    本发明涉及含氧胺盐的HMG-CoA还原酶抑制剂,涉及制备该胺盐的方法,以及使用该胺盐制备药用可接受的HMG-CoA还原酶抑制剂的方法。
  • [EN] AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN<br/>[FR] SELS D'AMINE DE LA PRAVASTATINE ET DE LA ROSUVASTATINE
    申请人:DSM SINOCHEM PHARM NL BV
    公开号:WO2014154856A8
    公开(公告)日:2014-11-27
查看更多